Gilead Sciences, Inc.
Alış
Güncellendi

GILD Scienced - GILD: Hepatitis Cures for C, B and D

208
FUNDAMENTALS:
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.

TECHNICALS:

Monthly: anlık görüntü
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence

Weekly: anlık görüntü
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support

Daily: anlık görüntü
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken




Not
Target: 165

Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.